BackRegenxbio Overview
Regenxbio Inc

Regenxbio Target Price

See Regenxbio's analyst price targets ($24) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$7.43

Average Target Price

$23.86221.1% upside

7 analysts in the last 4 months

High: $32 | Low: $18

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-25H.C. WainwrightYi Chen$21182.6% upsideOpen
2026-08-25Robert W. BairdBrian Skorney$29290.3% upsideOpen
2026-08-10H.C. Wainwright$23209.6% upsideOpen
2026-08-07Morgan StanleyJudah Frommer$18142.3% upsideOpen
2026-07-01H.C. WainwrightYi Chen$26249.9% upsideOpen
2026-06-22Leerink PartnersMani Foroohar$18142.3% upsideOpen
2026-06-22Robert W. BairdBrian Skorney$32330.7% upsideOpen
2026-05-15Morgan Stanley$16115.3% upsideOpen
2026-05-15BarclaysEliana Merle$1261.5% upsideOpen
2026-03-09H.C. Wainwright$30303.8% upsideOpen
2026-03-05Morgan StanleyJudah Frommer$17128.8% upsideOpen
2026-02-10H.C. Wainwright$32330.7% upsideOpen
2026-02-10Robert W. BairdBrian Skorney$27263.4% upsideOpen
2026-02-10UBS$18142.3% upsideOpen
2026-02-10Goldman Sachs$1261.5% upsideOpen
2026-01-29H.C. WainwrightYi Chen$34357.6% upsideOpen
2026-01-27Barclays$37398% upsideOpen
2025-12-19Stifel Nicolaus$45505.7% upsideOpen
2025-12-15Leerink PartnersMani Foroohar$20169.2% upsideOpen
2025-03-18Leerink Partners$24223% upsideOpen
2025-01-07RBC CapitalLuca Issi$30303.8% upsideOpen
2024-11-15Morgan StanleyJudah Frommer$22196.1% upsideOpen
2024-10-10Raymond JamesDanielle Brill$18142.3% upsideOpen
2024-09-05H.C. WainwrightYi Chen$39424.9% upsideOpen
2024-06-24Stifel NicolausAnnabel Samimy$40438.4% upsideOpen
2024-06-07Goldman SachsPaul Choi$38411.4% upsideOpen
2024-05-15H.C. WainwrightYi Chen$38411.4% upsideOpen
2024-03-11H.C. WainwrightYi Chen$36384.5% upsideOpen
2024-03-08RBC CapitalLuca Issi$35371.1% upsideOpen

Regenxbio (RGNX) FAQ

Regenxbio's target price stands at $24. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $24 for RGNX implies 221.1% upside versus today's price ($7.43). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Regenxbio's target price evolved across reporting periods, while the comparison chart places RGNX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Regenxbio's reading of $24 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.